A Fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers

Assay and Drug Development Technologies

Volumn 7, Issue 3, 2009, Pages 266-280

  Belardetti, Francesco ^a,c   Tringham, Elizabeth ^a   Eduljee, Cyrus ^a   Jiang, Xinpo ^a   Dong, Haiheng ^a,d   Hendricson, Adam ^a,e   Shimizu, Yoko ^a,f   Janke, Diana L ^a,g   Parker, David ^a   Mezeyova, Janette ^a   Khawaja, Afsheen ^a   Pajouhesh, Hassan ^a   Fraser, Robert A ^a,f   Arneric, Stephen P ^a,h   Snutch, Terrance P ^b  

^a Neuromed Pharmaceuticals   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Panora Pharmaceuticals Inc   (Canada)

^d WuXi Pharmatech   (China)

^e BRISTOL MYERS SQUIBB   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g WorkSafeBC   (Canada)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; GRAMICIDIN;

ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ALGORITHMS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, R-TYPE; CALCIUM CHANNELS, T-TYPE; CATION TRANSPORT PROTEINS; CELL LINE; DNA, COMPLEMENTARY; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; GRAMICIDIN; HUMANS; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; PHARMACEUTICAL SOLUTIONS; SPECTROMETRY, FLUORESCENCE;

EID: 70350170643     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.191     Document Type: Article

References (62)

1. Catterall WA: Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000;16:521-555.
2. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J: International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005;57:411-425.
3. Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, ef al:. Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature 1998;391:896-900. (Pubitemid 28157667)
4. Cribbs LL, Lee JH, Yang J, Satin J, Zhang Y, Daud A, etal:. Cloning and characterization of alpha 1H from human heart, a member of the T-type Ca2+ channel gene family. Ore Res 1998;83:103-109.
5. McRory JE, Santi CM, Hamming KS, Mezeyova J, Sutton KG, BaiHie DL, etal:. Molecular and functional characterization of a family of rat brain T-type calcium channels. J BiolChem 2001;276:3999-4011.
6. Perez-Reyes E: Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003;83:117-161.
7. Chen XL, Bayliss DA, Fern RJ, Barrett PQ: A role for T-type Ca2+ channels in the synergistic control of aldosterone production byANG II and K+. Am J Physiol 1999;276:F674-F683.
8. SchrierAD, Wang H, Talley EM, Perez-Reyes E, Barrett PQ: Alpha 1H T-type Ca2+channel is the predominant subtype expressed in bovine and rat zona glomerulosa. Am J Physiol Cell Physiol 2001 ;280:C265-C272.
9. Huguenard JR, Prince DA: A novel T-type current underlies prolonged Ca2+-dependent burst firing in GABAergic neurons of rat thalamic reticular nucleus. J Neurosci 1992;12:3804-3817.
10. Steriade M, McCormick DA, Sejnowski TJ: Thalamocortical oscillations in the sleeping and aroused brain. Science 1993;262:679-685.
11. Wolfart J, Roeper J: Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons. J Neurosci 2002;22:3404-3413.
12. Mangoni ME, Traboulsie A, Leoni AL, Couette B, Marger L, Le Quang K, etal:. Bradycardia and slowing of the atrioventricular conduction in mice lacking Cav3.lloelG T-type calcium channels. Ore Res 2006;98:1422-1430.
13. Kim D, Park D, Choi S, Lee S, Sun M, Kim C, ef al:. Thalamic control of visceral nociception mediated by T-type Ca2+ channels. Science 2003;302:117-119.
14. Na HS, Choi S, Kim J, Park J, Shin HS: Attenuated neuropathic pain in Cav3.1 null mice. Mol Cells 2008;25:242-246.
15. Kim D, Song I, Keum S, Lee T, Jeong MJ, Kim SS, etal:. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha1G T-type Ca2+ channels. Neuron 2001 ;31:35-45.
16. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot 0, etal:. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMB0 J 2005;24:315-324.
17. Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER, etal:. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 2007;27:3305-3316.
18. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, NaikAK, ef al: Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 2008;99:3151-3156.
19. Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, etal: Attenuated pain responses in mice lacking Cav3.2 T-type channels. Genes Brain Behav 2007;6:425-431.
20. Altier C, Zamponi GW: Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends PharmacolSci 2004;25:465-470.
21. Chen CC, Lamping KG, Nuno DW, Barresi R, Prouty SJ, Lavoie JL, etal: Abnormal coronary function in mice deficient in alpha 1H T-type Ca2+ channels. Science 2003;302:1416-1418.
22. Khosravani H, Zamponi GW: Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol Rev 2006;86:941-966.
23. Adams PJ, Snutch TP: Calcium channelopathies: voltage-gated calcium channels. Subcell Biochem 2007;45:215-251.
24. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T: Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-353.
25. Gray LS, Macdonald TL: The pharmacology and regulation of T type calcium channels: new opportunities for unique therapeutics for cancer. Cell Calcium 2006;40:115-120.
26. Panner A, Wurster RD: T-type calcium channels and tumor proliferation. Cell Calcium 2006;40:253-259.
27. Triggle DJ: Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996;78:7-12.
28. Triggle DJ: Calcium channel antagonists: clinical uses-past, present and future. Biochem Pharmacol 2007;74:1-9.
29. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, ef al: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 2002;22:396-403.
30. Nelson MT, Todorovic SM, Perez-Reyes E:The role of T-type calcium channels in epilepsy and pain. CurrPharm Des2006;12:2189-2197. (Pubitemid 43891394)
31. Vassort G, Talavera K, Alvarez JL: Role of T-type Ca2+ channels in the heart. Cell Calcium 2006;40:205-220.
32. Cribbs LL: T-type Ca2+ channels in vascular smooth muscle: multiple functions. CellCalcium 2006;40:221-230.
33. McGivern JG: Pharmacology and drug discovery for T-type calcium channels. CNS Neurol Disord Drug Targets 2006;5:587-603.
34. Shin HS, Cheong EJ, Choi S, Lee J, Na HS: T-type Ca2+ channels as therapeutic targets in the nervous system. Curr Opin Pharmacol 2008;8:33-41.
35. Belardetti F, Zamponi GW: Linking calcium-channel isoforms to potential therapies. Curr Opin Investig Drugs2008;9:707-715.
36. Myers VB, Haydon DA: Ion transfer across lipid membranes in the presence of gramicidin A. II. The ion selectivity. Biochim Biophys Acta 1972; 274:313-322.
37. Wallace BA: Common structural features in gramicidin and other ion channels. Bioessays 2000;22:227-234.
38. Miloshevsky GV, Jordan PC: Permeation in ion channels: the interplay of structure and theory. Trends Neurosci 2004;27:308-314.
39. Kelkar DA, Chattopadhyay A: The gramicidin ion channel: a model membrane protein. Biochim Biophys Acta 2007;1768:2011-2025.
40. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
41. Enyeart JJ, Biagi BA, Mlinar B: Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. Mol Pharmacol 1992;42:364-372.
42. 1L ) to neuronal excitability. J Physiol 2002, 540: 3-14.
43. Sogaard R, Ljungstrom T, Pedersen KA, Olesen SP, Jensen BS: KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol 2001 ;280:C859-C866.
44. Hille B: Ion Channels of Excitable Membranes. Sinauer Associates, Sunderland, MA, 2001.
45. DuaxWL, Griffin JF, Langs DA, Smith GD, Grochulski P, PletnevV, etal:. Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Biopolymers 1996;40:141-155.
46. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. PflugersArch 1981;391:85-100.
47. Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, etal:. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol 2008;6:195-212.
48. Lubin ML, ReitzTL, Todd MJ, FloresCM.Qin N.Xin H: A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye. Assay Drug Dev Technol 2006;4:689-694.
49. Xia M, ImredyJP, Koblan KS, Bennett P, Connolly TM: State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format. Anal Biochem 2004;327:74-81.
50. Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, ef al: Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem Pharmacol 2006;72:770-782.
51. XieX.Van Deusen AL.Vitko I, Babu DA, Davies LA, Huynh N, etal:. Validation of high throughput screening assays against three subtypes of Cav3 T-type channels using molecularand pharmacologic approaches. Assay Drug Dev Technol 2001;5:191-203.
52. Frankenhaeuser B, Hodgkin AL: The action of calcium on the electrical properties of squid axons. J Physiol 1957;137:218-244.
53. Tsai BS, Lefkowitz RJ: Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. Mol Pharmacol 1978;14:540-548.
54. Van der Kloot WG, Cohen I: Membrane surface potential changes may alter drug interactions: an example, acetylcholine and curare. Science 1979;203:1351-1352.
55. Kim T, Choi J, Kim S, Kwon 0, Nah SY, Han YS, etal:. The biochemical activation of T-type Ca2+ channels in HEK293 cells stably expressing oelG and Kir2.1 subunits. Biochem BiophysResCommun 2004;324:401-408.
56. Choi J, Park JH, Kwon 0Y, Kim S, Chung JH, Lim DS, etal:. T-type calcium channel trigger p21ras signaling pathway to ERK in Cav3.1-expressed HEK293 cells. Brain Res 2005;1054:22-29.
57. Fish RD, Sperti G, Colucci WS, Clapham DE: Phorbol ester increases the dihydropyridine-sensitive calcium conductance in a vascular smooth muscle cell line. Ore Res 1988;62:1049-1054.
58. Van Renterghem C, Romey G, Lazdunski M: Vasopressin modulates the spontaneous electrical activity in aortic cells (line A7r5) by acting on three different types of ionic channels. Proc Natl Acad Sci U S A 1988;85:9365-9369.
59. Krautwurst D, Degtiar VE, Schultz G, Hescheler J: The isoquinoline derivative LOE 908 selectively blocks vasopressin-activated nonselective cation currents in A7r5 aortic smooth muscle cells. Naunyn SchmiedebergsArch Pharmacol 1994;349:301-307.
60. Lorenz JN, Bielefeld DR, Sperelakis N: Regulation of calcium channel current in A7r5 vascular smooth muscle cells by cyclic nucleotides. Am J Physiol 1994;266:C1656-C1663.
61. Miwa S, Iwamuro Y, Zhang XF, Inoki T, Okamoto Y, Okazawa M, etal:. Ca2+entry channels in rat thoracic aortic smooth muscle cells activated by endothelin-1. Jpn Pharmacol 1999;80:281-288.
62. Tarroni P, Passafaro M, Polio A, Popoli M, Clementi F, Sher E: Anti-beta 2 subunit antisense oligonucleotides modulate the surface expression of the alpha 1 subunit of N-type omega-CTX sensitive Ca2+ channels in IMR 32 human neuroblastoma cells. Biochem Biophys Res Commun 1994;201:180-185.